RxDoctor Payments DataLook up a doctor →

Luis Garcia Barreto, MD

Pulmonary Disease · Coamo, PRNPI 1659450500

Payments from drug & device makers

$392,646in general payments, 2019–2025

Across 594 payments — averaging $661.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$199K
  • Pfizer$94K
  • Bayer$38K
  • Pfizer Pharmaceuticals LLC$35K
  • Merck$17K
  • AstraZeneca$4K
  • plus $6K from 20 others

What the payments were for

  • Consulting fees$3,0511%
  • Speaking & faculty fees$352,05890%
  • Travel & lodging$20,2605%
  • Food & beverage$17,1094%
  • Education$1510%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$392,646 in reported general payments places this provider in the 95th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,337
Medicare patients
29
Services billed
77

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat105$1,459,250
OpsumitMacitentan24$302,157
OfevNintedanib Esylate21$276,258
NucalaMepolizumab43$157,168
Stiolto RespimatTiotropium Br/Olodaterol Hcl283$140,133
Spiriva RespimatTiotropium Bromide224$124,839
Trelegy ElliptaFluticasone/Umeclidin/Vilanter161$106,888
Pirfenidone53$102,358
Breo ElliptaFluticasone/Vilanterol236$100,921
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate236$66,027
Dupixent SyringeDupilumab14$52,497
Albuterol Sulfate HfaAlbuterol Sulfate1,074$43,950
Theophylline ErTheophylline Anhydrous282$37,911
Arnuity ElliptaFluticasone Furoate135$36,505
Wixela InhubFluticasone Propion/Salmeterol198$32,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$38,255$1,459,250105 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$1,324$541,230528 claims
GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta$199,074$416,723603 claims
Actelion Pharmaceuticals US, Inc.Opsumit$216$302,15724 claims
AstraZenecaSymbicort, Breztri Aerosphere$3,602$44,166133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Coamo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →